Cargando…

Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure

Dyslipidemia commonly present in patients with chronic kidney disease (CKD) has been recently linked to increased proprotein convertase subtilisin/kexin type 9 (PCSK9) serum concentration. We tested a hypothesis that increased liver PCSK9 biosynthesis could be partially responsible for the elevated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sucajtys-Szulc, Elzbieta, Szolkiewicz, Marek, Swierczynski, Julian, Rutkowski, Boleslaw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737787/ https://www.ncbi.nlm.nih.gov/pubmed/26481479 http://dx.doi.org/10.1007/s11010-015-2590-0

Ejemplares similares

Hepatocyte nuclear factors as possible C-reactive protein transcriptional inducer in the liver and white adipose tissue of rats with experimental chronic renal failure
por: Sucajtys-Szulc, Elzbieta, et al.
Publicado: (2018)

Hepatocyte Nuclear Factor-1α Increases Fibrinogen Gene Expression in Liver and Plasma Fibrinogen Concentration in Rats with Experimental Chronic Renal Failure
por: Sucajtys-Szulc, Elzbieta, et al.
Publicado: (2023)

Hepatocyte Nuclear Factor 1α Proinflammatory Effect Linked to the Overexpression of Liver Nuclear Factor–κB in Experimental Model of Chronic Kidney Disease
por: Sucajtys-Szulc, Elzbieta, et al.
Publicado: (2022)

Up-regulation of PCSK9 gene expression and diminished level of LDL-receptor in rat liver as a potential cause of post-lipectomy hypercholesterolemia
por: Dettlaff-Pokora, Agnieszka, et al.
Publicado: (2018)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives
por: Catapano, Alberico Luigi, et al.
Publicado: (2017)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
por: Seidah, Nabil G.
Publicado: (2021)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018)

The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women
por: Evans, David, et al.
Publicado: (2006)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022)

Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
por: Shirahama, Ryo, et al.
Publicado: (2018)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia
por: Di Taranto, Maria Donata, et al.
Publicado: (2017)

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report
por: Pirazzi, Carlo, et al.
Publicado: (2019)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2017)

Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report
por: Ceballos-Macías, José Juan, et al.
Publicado: (2019)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
por: Cantin, Claudette, et al.
Publicado: (2022)

Dennd5b-Deficient Mice are Resistant to PCSK9-Induced Hypercholesterolemia and Diet-Induced Hepatic Steatosis
por: Mobilia, Maura, et al.
Publicado: (2022)

Allicin and Capsaicin Ameliorated Hypercholesterolemia by Upregulating LDLR and Downregulating PCSK9 Expression in HepG2 Cells
por: Nawaka, Nantiya, et al.
Publicado: (2022)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
por: Karatasakis, Aris, et al.
Publicado: (2017)

Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report
por: Bayona, Ane, et al.
Publicado: (2020)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tmhp1gcaqovfr7qav5u0pbng1r